Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

59.74
+0.98001.67%
Pre-market: 60.741.00+1.67%06:15 EDT
Volume:2.72M
Turnover:163.43M
Market Cap:9.93B
PE:-17.17
High:60.92
Open:59.64
Low:59.06
Close:58.76
52wk High:86.74
52wk Low:41.71
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.15
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.58
PE(LYR):-25.09

Loading ...

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza to be Available in U.S. for Shtg in July

THOMSON REUTERS
·
Jun 25

FDA: Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Jun 25

Ionis' Tryngolza Receives FDA Approval to Treat Acute Pancreatitis in Severe Hypertriglyceridemia Patients

MT Newswires Live
·
Jun 25

FDA announces approval of Ionis’ Tryngolza for hypertriglyceridemia

TIPRANKS
·
Jun 24

How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Ionis director Spencer R. Berthelsen sells 8,000 shares worth $587,920

Reuters
·
Jun 17